GSK joins arch-rival Pfizer in the market for five-in-one meningococcal vaccines with FDA approval for Penmenvy, a top launch prospect for 2025. Johnson & Johnson and Sanofi's vaccine for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback